{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cequa&page=16", "query": { "intervention": "Cequa", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 565, "total_pages": 57, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cequa&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cequa&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T11:09:14.081Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00074490", "title": "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia", "Myeloproliferative Disorders", "Multiple Myleoma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Peripheral blood stem cell (PBSC) transplantation", "type": "PROCEDURE" }, { "name": "T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells", "type": "GENETIC" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Allogeneic hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "T-Rapa cell Donor Lymphocyte Infusion (DLI)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "11 Years to 90 Years" }, "enrollment_count": 442, "start_date": "2004-01-01", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2018-12-31", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074490" }, { "nct_id": "NCT00658359", "title": "Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 178, "start_date": "2008-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 37, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658359" }, { "nct_id": "NCT00977977", "title": "Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nephrotic Syndrome", "Proteinuria", "Autoimmune Disease", "Glomerular Disease", "Membranous Glomerulonephritis" ], "interventions": [ { "name": "Rituximab Infusion", "type": "DRUG" }, { "name": "Oral Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2010-12-22", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00977977" }, { "nct_id": "NCT00098007", "title": "A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Transplantation" ], "interventions": [ { "name": "Everolimus (Certican)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 199, "start_date": "2004-08-09", "completion_date": "2007-01-08", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098007" }, { "nct_id": "NCT00099736", "title": "Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids", "type": "DRUG" }, { "name": "FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids", "type": "DRUG" }, { "name": "MMF 2 g + full-dose Neoral (FDN) + corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 696, "start_date": "2003-05-07", "completion_date": "2005-09-19", "has_results": false, "last_update_posted_date": "2017-08-22", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00099736" }, { "nct_id": "NCT00477763", "title": "Oasys vs. Extreme H20 Xtra 59", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dry Eye" ], "interventions": [ { "name": "Restasis, Refresh Endura", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovative Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 52, "start_date": "2007-05", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2008-02-18", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 1, "location_summary": "Hazleton, Pennsylvania", "locations": [ { "city": "Hazleton", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477763" }, { "nct_id": "NCT01252667", "title": "Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 44, "start_date": "2011-01-25", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2020-04-16", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 4, "location_summary": "Aurora, Colorado • New Orleans, Louisiana • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252667" }, { "nct_id": "NCT00619645", "title": "Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 8, "start_date": "2007-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619645" }, { "nct_id": "NCT00796068", "title": "Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia in Remission", "Blasts Under 5 Percent of Bone Marrow Nucleated Cells", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Treosulfan", "type": "DRUG" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 130, "start_date": "2009-02-24", "completion_date": "2021-12-14", "has_results": true, "last_update_posted_date": "2023-02-17", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 3, "location_summary": "Aurora, Colorado • Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796068" }, { "nct_id": "NCT01868360", "title": "Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Corneal Neovascularization" ], "interventions": [ { "name": "Subconjunctival aflibercept", "type": "DRUG" }, { "name": "Placebo: Standard of care only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Balamurali Ambati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-10-07", "last_synced_at": "2026-11-14T11:09:14.081Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01868360" } ] }